SCHEMBL22556475

SCHEMBL22556475

CCN(CC(=O)NNC(=O)c1ccccc1Nc1ccc(C(F)(F)F)cc1)C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RXFP1 Q9HBX9 9/20 0.47
▸ TAS2R14 Q9NYV8 3/20 0.42
▸ AKR1C3 P42330 1/20 0.42
▸ AKR1C2 P52895 1/20 0.42
▸ KMT2A Q03164 3/20 0.41
▸ MAPK8 P45983 1/20 0.41
▸ MEN1 O00255 2/20 0.40
▸ PPARG P37231 1/20 0.40
▸ PPARD Q03181 1/20 0.40
▸ PPARA Q07869 1/20 0.40
▸ NR1H4 Q96RI1 1/20 0.40
▸ MTOR P42345 1/20 0.40
▸ ABCG2 Q9UNQ0 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23701547 0.90 RXFP1 (0.45) RXFP1TAS2R14AKR1C3AKR1C2KMT2A
SCHEMBL23701543 0.87 RXFP1 (0.48) RXFP1TAS2R14AKR1C3AKR1C2KMT2A
SCHEMBL22571429 0.87 RXFP1 (0.46) RXFP1TAS2R14KMT2AMAPK8MEN1
SCHEMBL30463789 0.87 RXFP1 (0.46) RXFP1TAS2R14KMT2AMAPK8MEN1
SCHEMBL22556339 0.84 PSMB5 (0.46) RXFP1TAS2R14AKR1C3AKR1C2KMT2A
SCHEMBL22571350 0.84 RXFP1 (0.51) RXFP1TAS2R14AKR1C3AKR1C2KMT2A
SCHEMBL23701523 0.81 RXFP1 (0.47) RXFP1TAS2R14AKR1C3AKR1C2KMT2A
SCHEMBL23701621 0.80 RXFP1 (0.46) RXFP1TAS2R14AKR1C3AKR1C2KMT2A
SCHEMBL22571446 0.80 RXFP1 (0.44) RXFP1KMT2AMAPK8PPARGPPARD
SCHEMBL30463783 0.80 RXFP1 (0.44) RXFP1KMT2AMAPK8PPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11661403-B2 Oxadiazole compounds VIVACE THERAPEUTICS, INC. (US) 2023-05-30 — — US disclosed
US-20210238154-A1 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. 2021-08-05 — — US disclosed
EP-3793551-A1 OXADIAZOLE COMPOUNDS Vivace Therapeutics, Inc. (US) 2021-03-24 — — EP disclosed
WO-2019222431-A9 OXADIAZOLE COMPOUNDS VIVACE THERAPEUTICS, INC. (US) 2020-10-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210238154-A1 OXADIAZOLE COMPOUNDS YAP1, TEAD2, TEAD3 RXFP1 3511/4885TAS2R14 4508/4885AKR1C3 4073/4885
US-11661403-B2 Oxadiazole compounds YAP1, TEAD2, TEAD3 RXFP1 3511/4885TAS2R14 4508/4885AKR1C3 4073/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback